- call +1-201-465-4211
- email sales@marketsandresearch.biz
- Call +1-201-465-4211
- Email: sales@marketsandresearch.biz
The Benign Prostatic Hyperplasia (BPH) Drugs market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.
According to our latest study, due to COVID-19 pandemic, the global Benign Prostatic Hyperplasia (BPH) Drugs market size is estimated to be worth US$ 3425.9 million in 2021 and is forecast to a readjusted size of USD 4258.9 million by 2028 with a CAGR of 3.2% during review period. Hospitals accounting for % of the Benign Prostatic Hyperplasia (BPH) Drugs global market in 2021, is projected to value USD million by 2028, growing at a % CAGR in next six years. While Alpha-Blocker segment is altered to a % CAGR between 2022 and 2028.
Global key manufacturers of Benign Prostatic Hyperplasia (BPH) Drugs include Eli Lilly, GlaxoSmithKline, Astellas Pharma, Sanofi, and Pfizer, etc. In terms of revenue, the global top four players hold a share over % in 2021.
Market segmentation
Benign Prostatic Hyperplasia (BPH) Drugs market is split by Type and by Application. For the period 2017-2028, the growth among segments provide accurate calculations and forecasts for sales by Type and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type, covers
Alpha-Blocker
Phosphodiesterase Type-5 Inhibitors
Others
Market segment by Application can be divided into
Hospitals
Drugstores
Others
The key market players for global Benign Prostatic Hyperplasia (BPH) Drugs market are listed below:
Eli Lilly
GlaxoSmithKline
Astellas Pharma
Sanofi
Pfizer
Abbott
Allergan
TEVA
Mylan
Novartis
Merck
Market segment by region, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Benign Prostatic Hyperplasia (BPH) Drugs product scope, market overview, market opportunities, market driving force and market risks.
Chapter 2, to profile the top manufacturers of Benign Prostatic Hyperplasia (BPH) Drugs, with price, sales, revenue and global market share of Benign Prostatic Hyperplasia (BPH) Drugs from 2019 to 2022.
Chapter 3, the Benign Prostatic Hyperplasia (BPH) Drugs competitive situation, sales, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Benign Prostatic Hyperplasia (BPH) Drugs breakdown data are shown at the regional level, to show the sales, revenue and growth by regions, from 2017 to 2028.
Chapter 5 and 6, to segment the sales by Type and application, with sales market share and growth rate by type, application, from 2017 to 2028.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales, revenue and market share for key countries in the world, from 2017 to 2022.and Benign Prostatic Hyperplasia (BPH) Drugs market forecast, by regions, type and application, with sales and revenue, from 2023 to 2028.
Chapter 12, the key raw materials and key suppliers, and industry chain of Benign Prostatic Hyperplasia (BPH) Drugs.
Chapter 13, 14, and 15, to describe Benign Prostatic Hyperplasia (BPH) Drugs sales channel, distributors, customers, research findings and conclusion, appendix and data source.
The base year for the study has been considered 2019, historic year 2014 and 2018, the forecast period considered is from 2020 to 2027. The regions analyzed for the market include North America, Europe, South America, Asia Pacific, and Middle East and Africa. These regions are further analyzed at the country-level. The study also includes attractiveness analysis of type, application and regions which are benchmarked based on their market size, growth rate and attractiveness in terms of present and future opportunity for understanding the future growth of the market.
Market is segmented on the basis:
The report offers in-depth analysis of driving factors, opportunities, restraints, and challenges for gaining the key insight of the market. The report emphasizes on all the key trends that play a vital role in the enlargement of the market from 2019 to 2026.
The report provides company profile of the key players operating in the market and a comparative analysis based on their business overviews industry offering, segment market share, regional presence, business strategies, innovations, mergers & acquisitions, recent developments, joint venture, collaborations, partnerships, SWOT analysis, and key financial information.
1 Market Overview
1.1 Benign Prostatic Hyperplasia (BPH) Drugs Introduction
1.2 Market Analysis by Type
1.2.1 Overview: Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Type: 2017 Versus 2021 Versus 2028
1.2.2 Alpha-Blocker
1.2.3 Phosphodiesterase Type-5 Inhibitors
1.2.4 Others
1.3 Market Analysis by Application
1.3.1 Overview: Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Application: 2017 Versus 2021 Versus 2028
1.3.2 Hospitals
1.3.3 Drugstores
1.3.4 Others
1.4 Global Benign Prostatic Hyperplasia (BPH) Drugs Market Size & Forecast
1.4.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Sales in Value (2017 & 2021 & 2028)
1.4.2 Global Benign Prostatic Hyperplasia (BPH) Drugs Sales in Volume (2017-2028)
1.4.3 Global Benign Prostatic Hyperplasia (BPH) Drugs Price (2017-2028)
1.5 Global Benign Prostatic Hyperplasia (BPH) Drugs Production Capacity Analysis
1.5.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Total Production Capacity (2017-2028)
1.5.2 Global Benign Prostatic Hyperplasia (BPH) Drugs Production Capacity by Geographic Region
1.6 Market Drivers, Restraints and Trends
1.6.1 Benign Prostatic Hyperplasia (BPH) Drugs Market Drivers
1.6.2 Benign Prostatic Hyperplasia (BPH) Drugs Market Restraints
1.6.3 Benign Prostatic Hyperplasia (BPH) Drugs Trends Analysis
2 Manufacturers Profiles
2.1 Eli Lilly
2.1.1 Eli Lilly Details
2.1.2 Eli Lilly Major Business
2.1.3 Eli Lilly Benign Prostatic Hyperplasia (BPH) Drugs Product and Services
2.1.4 Eli Lilly Benign Prostatic Hyperplasia (BPH) Drugs Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.2 GlaxoSmithKline
2.2.1 GlaxoSmithKline Details
2.2.2 GlaxoSmithKline Major Business
2.2.3 GlaxoSmithKline Benign Prostatic Hyperplasia (BPH) Drugs Product and Services
2.2.4 GlaxoSmithKline Benign Prostatic Hyperplasia (BPH) Drugs Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.3 Astellas Pharma
2.3.1 Astellas Pharma Details
2.3.2 Astellas Pharma Major Business
2.3.3 Astellas Pharma Benign Prostatic Hyperplasia (BPH) Drugs Product and Services
2.3.4 Astellas Pharma Benign Prostatic Hyperplasia (BPH) Drugs Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.4 Sanofi
2.4.1 Sanofi Details
2.4.2 Sanofi Major Business
2.4.3 Sanofi Benign Prostatic Hyperplasia (BPH) Drugs Product and Services
2.4.4 Sanofi Benign Prostatic Hyperplasia (BPH) Drugs Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.5 Pfizer
2.5.1 Pfizer Details
2.5.2 Pfizer Major Business
2.5.3 Pfizer Benign Prostatic Hyperplasia (BPH) Drugs Product and Services
2.5.4 Pfizer Benign Prostatic Hyperplasia (BPH) Drugs Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.6 Abbott
2.6.1 Abbott Details
2.6.2 Abbott Major Business
2.6.3 Abbott Benign Prostatic Hyperplasia (BPH) Drugs Product and Services
2.6.4 Abbott Benign Prostatic Hyperplasia (BPH) Drugs Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.7 Allergan
2.7.1 Allergan Details
2.7.2 Allergan Major Business
2.7.3 Allergan Benign Prostatic Hyperplasia (BPH) Drugs Product and Services
2.7.4 Allergan Benign Prostatic Hyperplasia (BPH) Drugs Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.8 TEVA
2.8.1 TEVA Details
2.8.2 TEVA Major Business
2.8.3 TEVA Benign Prostatic Hyperplasia (BPH) Drugs Product and Services
2.8.4 TEVA Benign Prostatic Hyperplasia (BPH) Drugs Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.9 Mylan
2.9.1 Mylan Details
2.9.2 Mylan Major Business
2.9.3 Mylan Benign Prostatic Hyperplasia (BPH) Drugs Product and Services
2.9.4 Mylan Benign Prostatic Hyperplasia (BPH) Drugs Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.10 Novartis
2.10.1 Novartis Details
2.10.2 Novartis Major Business
2.10.3 Novartis Benign Prostatic Hyperplasia (BPH) Drugs Product and Services
2.10.4 Novartis Benign Prostatic Hyperplasia (BPH) Drugs Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.11 Merck
2.11.1 Merck Details
2.11.2 Merck Major Business
2.11.3 Merck Benign Prostatic Hyperplasia (BPH) Drugs Product and Services
2.11.4 Merck Benign Prostatic Hyperplasia (BPH) Drugs Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
3 Benign Prostatic Hyperplasia (BPH) Drugs Breakdown Data by Manufacturer
3.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Sales in Volume by Manufacturer (2019, 2020, 2021, and 2022)
3.2 Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Manufacturer (2019, 2020, 2021, and 2022)
3.3 Key Manufacturer Market Position in Benign Prostatic Hyperplasia (BPH) Drugs
3.4 Market Concentration Rate
3.4.1 Top 3 Benign Prostatic Hyperplasia (BPH) Drugs Manufacturer Market Share in 2021
3.4.2 Top 6 Benign Prostatic Hyperplasia (BPH) Drugs Manufacturer Market Share in 2021
3.5 Global Benign Prostatic Hyperplasia (BPH) Drugs Production Capacity by Company: 2021 VS 2022
3.6 Manufacturer by Geography: Head Office and Benign Prostatic Hyperplasia (BPH) Drugs Production Site
3.7 New Entrant and Capacity Expansion Plans
3.8 Mergers & Acquisitions
4 Market Analysis by Region
4.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Market Size by Region
4.1.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Sales in Volume by Region (2017-2028)
4.1.2 Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Region (2017-2028)
4.2 North America Benign Prostatic Hyperplasia (BPH) Drugs Revenue (2017-2028)
4.3 Europe Benign Prostatic Hyperplasia (BPH) Drugs Revenue (2017-2028)
4.4 Asia-Pacific Benign Prostatic Hyperplasia (BPH) Drugs Revenue (2017-2028)
4.5 South America Benign Prostatic Hyperplasia (BPH) Drugs Revenue (2017-2028)
4.6 Middle East and Africa Benign Prostatic Hyperplasia (BPH) Drugs Revenue (2017-2028)
5 Market Segment by Type
5.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Sales in Volume by Type (2017-2028)
5.2 Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Type (2017-2028)
5.3 Global Benign Prostatic Hyperplasia (BPH) Drugs Price by Type (2017-2028)
6 Market Segment by Application
6.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Sales in Volume by Application (2017-2028)
6.2 Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Application (2017-2028)
6.3 Global Benign Prostatic Hyperplasia (BPH) Drugs Price by Application (2017-2028)
7 North America by Country, by Type, and by Application
7.1 North America Benign Prostatic Hyperplasia (BPH) Drugs Sales by Type (2017-2028)
7.2 North America Benign Prostatic Hyperplasia (BPH) Drugs Sales by Application (2017-2028)
7.3 North America Benign Prostatic Hyperplasia (BPH) Drugs Market Size by Country
7.3.1 North America Benign Prostatic Hyperplasia (BPH) Drugs Sales in Volume by Country (2017-2028)
7.3.2 North America Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Country (2017-2028)
7.3.3 United States Market Size and Forecast (2017-2028)
7.3.4 Canada Market Size and Forecast (2017-2028)
7.3.5 Mexico Market Size and Forecast (2017-2028)
8 Europe by Country, by Type, and by Application
8.1 Europe Benign Prostatic Hyperplasia (BPH) Drugs Sales by Type (2017-2028)
8.2 Europe Benign Prostatic Hyperplasia (BPH) Drugs Sales by Application (2017-2028)
8.3 Europe Benign Prostatic Hyperplasia (BPH) Drugs Market Size by Country
8.3.1 Europe Benign Prostatic Hyperplasia (BPH) Drugs Sales in Volume by Country (2017-2028)
8.3.2 Europe Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Country (2017-2028)
8.3.3 Germany Market Size and Forecast (2017-2028)
8.3.4 France Market Size and Forecast (2017-2028)
8.3.5 United Kingdom Market Size and Forecast (2017-2028)
8.3.6 Russia Market Size and Forecast (2017-2028)
8.3.7 Italy Market Size and Forecast (2017-2028)
9 Asia-Pacific by Region, by Type, and by Application
9.1 Asia-Pacific Benign Prostatic Hyperplasia (BPH) Drugs Sales by Type (2017-2028)
9.2 Asia-Pacific Benign Prostatic Hyperplasia (BPH) Drugs Sales by Application (2017-2028)
9.3 Asia-Pacific Benign Prostatic Hyperplasia (BPH) Drugs Market Size by Region
9.3.1 Asia-Pacific Benign Prostatic Hyperplasia (BPH) Drugs Sales in Volume by Region (2017-2028)
9.3.2 Asia-Pacific Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Region (2017-2028)
9.3.3 China Market Size and Forecast (2017-2028)
9.3.4 Japan Market Size and Forecast (2017-2028)
9.3.5 Korea Market Size and Forecast (2017-2028)
9.3.6 India Market Size and Forecast (2017-2028)
9.3.7 Southeast Asia Market Size and Forecast (2017-2028)
9.3.8 Australia Market Size and Forecast (2017-2028)
10 South America by Region, by Type, and by Application
10.1 South America Benign Prostatic Hyperplasia (BPH) Drugs Sales by Type (2017-2028)
10.2 South America Benign Prostatic Hyperplasia (BPH) Drugs Sales by Application (2017-2028)
10.3 South America Benign Prostatic Hyperplasia (BPH) Drugs Market Size by Country
10.3.1 South America Benign Prostatic Hyperplasia (BPH) Drugs Sales in Volume by Country (2017-2028)
10.3.2 South America Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Country (2017-2028)
10.3.3 Brazil Market Size and Forecast (2017-2028)
10.3.4 Argentina Market Size and Forecast (2017-2028)
11 Middle East & Africa by Country, by Type, and by Application
11.1 Middle East & Africa Benign Prostatic Hyperplasia (BPH) Drugs Sales by Type (2017-2028)
11.2 Middle East & Africa Benign Prostatic Hyperplasia (BPH) Drugs Sales by Application (2017-2028)
11.3 Middle East & Africa Benign Prostatic Hyperplasia (BPH) Drugs Market Size by Country
11.3.1 Middle East & Africa Benign Prostatic Hyperplasia (BPH) Drugs Sales in Volume by Country (2017-2028)
11.3.2 Middle East & Africa Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Country (2017-2028)
11.3.3 Turkey Market Size and Forecast (2017-2028)
11.3.4 Egypt Market Size and Forecast (2017-2028)
11.3.5 Saudi Arabia Market Size and Forecast (2017-2028)
11.3.6 South Africa Market Size and Forecast (2017-2028)
12 Raw Material and Industry Chain
12.1 Raw Material of Benign Prostatic Hyperplasia (BPH) Drugs and Key Manufacturers
12.2 Manufacturing Costs Percentage of Benign Prostatic Hyperplasia (BPH) Drugs
12.3 Benign Prostatic Hyperplasia (BPH) Drugs Production Process
12.4 Benign Prostatic Hyperplasia (BPH) Drugs Industrial Chain
13 Sales Channel, Distributors, Traders and Dealers
13.1 Sales Channel
13.1.1 Direct Marketing
13.1.2 Indirect Marketing
13.2 Benign Prostatic Hyperplasia (BPH) Drugs Typical Distributors
13.3 Benign Prostatic Hyperplasia (BPH) Drugs Typical Customers
14 Research Findings and Conclusion
15 Appendix
15.1 Methodology
15.2 Research Process and Data Source
15.3 Disclaimer
List of Tables
Table 1. Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Type, (USD Million), 2017 & 2021 & 2028
Table 2. Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Application, (USD Million), 2017 & 2021 & 2028
Table 3. Eli Lilly Basic Information, Manufacturing Base and Competitors
Table 4. Eli Lilly Major Business
Table 5. Eli Lilly Benign Prostatic Hyperplasia (BPH) Drugs Product and Services
Table 6. Eli Lilly Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 7. GlaxoSmithKline Basic Information, Manufacturing Base and Competitors
Table 8. GlaxoSmithKline Major Business
Table 9. GlaxoSmithKline Benign Prostatic Hyperplasia (BPH) Drugs Product and Services
Table 10. GlaxoSmithKline Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 11. Astellas Pharma Basic Information, Manufacturing Base and Competitors
Table 12. Astellas Pharma Major Business
Table 13. Astellas Pharma Benign Prostatic Hyperplasia (BPH) Drugs Product and Services
Table 14. Astellas Pharma Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 15. Sanofi Basic Information, Manufacturing Base and Competitors
Table 16. Sanofi Major Business
Table 17. Sanofi Benign Prostatic Hyperplasia (BPH) Drugs Product and Services
Table 18. Sanofi Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 19. Pfizer Basic Information, Manufacturing Base and Competitors
Table 20. Pfizer Major Business
Table 21. Pfizer Benign Prostatic Hyperplasia (BPH) Drugs Product and Services
Table 22. Pfizer Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 23. Abbott Basic Information, Manufacturing Base and Competitors
Table 24. Abbott Major Business
Table 25. Abbott Benign Prostatic Hyperplasia (BPH) Drugs Product and Services
Table 26. Abbott Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 27. Allergan Basic Information, Manufacturing Base and Competitors
Table 28. Allergan Major Business
Table 29. Allergan Benign Prostatic Hyperplasia (BPH) Drugs Product and Services
Table 30. Allergan Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 31. TEVA Basic Information, Manufacturing Base and Competitors
Table 32. TEVA Major Business
Table 33. TEVA Benign Prostatic Hyperplasia (BPH) Drugs Product and Services
Table 34. TEVA Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 35. Mylan Basic Information, Manufacturing Base and Competitors
Table 36. Mylan Major Business
Table 37. Mylan Benign Prostatic Hyperplasia (BPH) Drugs Product and Services
Table 38. Mylan Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 39. Novartis Basic Information, Manufacturing Base and Competitors
Table 40. Novartis Major Business
Table 41. Novartis Benign Prostatic Hyperplasia (BPH) Drugs Product and Services
Table 42. Novartis Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 43. Merck Basic Information, Manufacturing Base and Competitors
Table 44. Merck Major Business
Table 45. Merck Benign Prostatic Hyperplasia (BPH) Drugs Product and Services
Table 46. Merck Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 47. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales by Manufacturer (2019, 2020, 2021, and 2022) & (M Units)
Table 48. Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Manufacturer (2019, 2020, 2021, and 2022) & (USD Million)
Table 49. Market Position of Manufacturers in Benign Prostatic Hyperplasia (BPH) Drugs, (Tier 1, Tier 2, and Tier 3), Based on Revenue in 2021
Table 50. Global Benign Prostatic Hyperplasia (BPH) Drugs Production Capacity by Company, (M Units): 2020 VS 2021
Table 51. Head Office and Benign Prostatic Hyperplasia (BPH) Drugs Production Site of Key Manufacturer
Table 52. Benign Prostatic Hyperplasia (BPH) Drugs New Entrant and Capacity Expansion Plans
Table 53. Benign Prostatic Hyperplasia (BPH) Drugs Mergers & Acquisitions in the Past Five Years
Table 54. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales by Region (2017-2022) & (M Units)
Table 55. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales by Region (2023-2028) & (M Units)
Table 56. Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Region (2017-2022) & (USD Million)
Table 57. Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Region (2023-2028) & (USD Million)
Table 58. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales by Type (2017-2022) & (M Units)
Table 59. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales by Type (2023-2028) & (M Units)
Table 60. Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Type (2017-2022) & (USD Million)
Table 61. Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Type (2023-2028) & (USD Million)
Table 62. Global Benign Prostatic Hyperplasia (BPH) Drugs Price by Type (2017-2022) & (US$/Unit)
Table 63. Global Benign Prostatic Hyperplasia (BPH) Drugs Price by Type (2023-2028) & (US$/Unit)
Table 64. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales by Application (2017-2022) & (M Units)
Table 65. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales by Application (2023-2028) & (M Units)
Table 66. Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Application (2017-2022) & (USD Million)
Table 67. Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Application (2023-2028) & (USD Million)
Table 68. Global Benign Prostatic Hyperplasia (BPH) Drugs Price by Application (2017-2022) & (US$/Unit)
Table 69. Global Benign Prostatic Hyperplasia (BPH) Drugs Price by Application (2023-2028) & (US$/Unit)
Table 70. North America Benign Prostatic Hyperplasia (BPH) Drugs Sales by Country (2017-2022) & (M Units)
Table 71. North America Benign Prostatic Hyperplasia (BPH) Drugs Sales by Country (2023-2028) & (M Units)
Table 72. North America Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Country (2017-2022) & (USD Million)
Table 73. North America Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Country (2023-2028) & (USD Million)
Table 74. North America Benign Prostatic Hyperplasia (BPH) Drugs Sales by Type (2017-2022) & (M Units)
Table 75. North America Benign Prostatic Hyperplasia (BPH) Drugs Sales by Type (2023-2028) & (M Units)
Table 76. North America Benign Prostatic Hyperplasia (BPH) Drugs Sales by Application (2017-2022) & (M Units)
Table 77. North America Benign Prostatic Hyperplasia (BPH) Drugs Sales by Application (2023-2028) & (M Units)
Table 78. Europe Benign Prostatic Hyperplasia (BPH) Drugs Sales by Country (2017-2022) & (M Units)
Table 79. Europe Benign Prostatic Hyperplasia (BPH) Drugs Sales by Country (2023-2028) & (M Units)
Table 80. Europe Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Country (2017-2022) & (USD Million)
Table 81. Europe Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Country (2023-2028) & (USD Million)
Table 82. Europe Benign Prostatic Hyperplasia (BPH) Drugs Sales by Type (2017-2022) & (M Units)
Table 83. Europe Benign Prostatic Hyperplasia (BPH) Drugs Sales by Type (2023-2028) & (M Units)
Table 84. Europe Benign Prostatic Hyperplasia (BPH) Drugs Sales by Application (2017-2022) & (M Units)
Table 85. Europe Benign Prostatic Hyperplasia (BPH) Drugs Sales by Application (2023-2028) & (M Units)
Table 86. Asia-Pacific Benign Prostatic Hyperplasia (BPH) Drugs Sales by Region (2017-2022) & (M Units)
Table 87. Asia-Pacific Benign Prostatic Hyperplasia (BPH) Drugs Sales by Region (2023-2028) & (M Units)
Table 88. Asia-Pacific Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Region (2017-2022) & (USD Million)
Table 89. Asia-Pacific Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Region (2023-2028) & (USD Million)
Table 90. Asia-Pacific Benign Prostatic Hyperplasia (BPH) Drugs Sales by Type (2017-2022) & (M Units)
Table 91. Asia-Pacific Benign Prostatic Hyperplasia (BPH) Drugs Sales by Type (2023-2028) & (M Units)
Table 92. Asia-Pacific Benign Prostatic Hyperplasia (BPH) Drugs Sales by Application (2017-2022) & (M Units)
Table 93. Asia-Pacific Benign Prostatic Hyperplasia (BPH) Drugs Sales by Application (2023-2028) & (M Units)
Table 94. South America Benign Prostatic Hyperplasia (BPH) Drugs Sales by Country (2017-2022) & (M Units)
Table 95. South America Benign Prostatic Hyperplasia (BPH) Drugs Sales by Country (2023-2028) & (M Units)
Table 96. South America Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Country (2017-2022) & (USD Million)
Table 97. South America Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Country (2023-2028) & (USD Million)
Table 98. South America Benign Prostatic Hyperplasia (BPH) Drugs Sales by Type (2017-2022) & (M Units)
Table 99. South America Benign Prostatic Hyperplasia (BPH) Drugs Sales by Type (2023-2028) & (M Units)
Table 100. South America Benign Prostatic Hyperplasia (BPH) Drugs Sales by Application (2017-2022) & (M Units)
Table 101. South America Benign Prostatic Hyperplasia (BPH) Drugs Sales by Application (2023-2028) & (M Units)
Table 102. Middle East & Africa Benign Prostatic Hyperplasia (BPH) Drugs Sales by Region (2017-2022) & (M Units)
Table 103. Middle East & Africa Benign Prostatic Hyperplasia (BPH) Drugs Sales by Region (2023-2028) & (M Units)
Table 104. Middle East & Africa Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Region (2017-2022) & (USD Million)
Table 105. Middle East & Africa Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Region (2023-2028) & (USD Million)
Table 106. Middle East & Africa Benign Prostatic Hyperplasia (BPH) Drugs Sales by Type (2017-2022) & (M Units)
Table 107. Middle East & Africa Benign Prostatic Hyperplasia (BPH) Drugs Sales by Type (2023-2028) & (M Units)
Table 108. Middle East & Africa Benign Prostatic Hyperplasia (BPH) Drugs Sales by Application (2017-2022) & (M Units)
Table 109. Middle East & Africa Benign Prostatic Hyperplasia (BPH) Drugs Sales by Application (2023-2028) & (M Units)
Table 110. Benign Prostatic Hyperplasia (BPH) Drugs Raw Material
Table 111. Key Manufacturers of Benign Prostatic Hyperplasia (BPH) Drugs Raw Materials
Table 112. Direct Channel Pros & Cons
Table 113. Indirect Channel Pros & Cons
Table 114. Benign Prostatic Hyperplasia (BPH) Drugs Typical Distributors
Table 115. Benign Prostatic Hyperplasia (BPH) Drugs Typical Customers
List of Figures
Figure 1. Benign Prostatic Hyperplasia (BPH) Drugs Picture
Figure 2. Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Type in 2021
Figure 3. Alpha-Blocker
Figure 4. Phosphodiesterase Type-5 Inhibitors
Figure 5. Others
Figure 6. Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Application in 2021
Figure 7. Hospitals
Figure 8. Drugstores
Figure 9. Others
Figure 10. Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue, (USD Million) & (M Units): 2017 & 2021 & 2028
Figure 11. Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue and Forecast (2017-2028) & (USD Million)
Figure 12. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales (2017-2028) & (M Units)
Figure 13. Global Benign Prostatic Hyperplasia (BPH) Drugs Price (2017-2028) & (US$/Unit)
Figure 14. Global Benign Prostatic Hyperplasia (BPH) Drugs Production Capacity (2017-2028) & (M Units)
Figure 15. Global Benign Prostatic Hyperplasia (BPH) Drugs Production Capacity by Geographic Region: 2022 VS 2028
Figure 16. Benign Prostatic Hyperplasia (BPH) Drugs Market Drivers
Figure 17. Benign Prostatic Hyperplasia (BPH) Drugs Market Restraints
Figure 18. Benign Prostatic Hyperplasia (BPH) Drugs Market Trends
Figure 19. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Manufacturer in 2021
Figure 20. Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Manufacturer in 2021
Figure 21. Benign Prostatic Hyperplasia (BPH) Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3) in 2021
Figure 22. Top 3 Benign Prostatic Hyperplasia (BPH) Drugs Manufacturer (Revenue) Market Share in 2021
Figure 23. Top 6 Benign Prostatic Hyperplasia (BPH) Drugs Manufacturer (Revenue) Market Share in 2021
Figure 24. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Region (2017-2028)
Figure 25. Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Region (2017-2028)
Figure 26. North America Benign Prostatic Hyperplasia (BPH) Drugs Revenue (2017-2028) & (USD Million)
Figure 27. Europe Benign Prostatic Hyperplasia (BPH) Drugs Revenue (2017-2028) & (USD Million)
Figure 28. Asia-Pacific Benign Prostatic Hyperplasia (BPH) Drugs Revenue (2017-2028) & (USD Million)
Figure 29. South America Benign Prostatic Hyperplasia (BPH) Drugs Revenue (2017-2028) & (USD Million)
Figure 30. Middle East & Africa Benign Prostatic Hyperplasia (BPH) Drugs Revenue (2017-2028) & (USD Million)
Figure 31. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Type (2017-2028)
Figure 32. Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Type (2017-2028)
Figure 33. Global Benign Prostatic Hyperplasia (BPH) Drugs Price by Type (2017-2028) & (US$/Unit)
Figure 34. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Application (2017-2028)
Figure 35. Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Application (2017-2028)
Figure 36. Global Benign Prostatic Hyperplasia (BPH) Drugs Price by Application (2017-2028) & (US$/Unit)
Figure 37. North America Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Type (2017-2028)
Figure 38. North America Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Application (2017-2028)
Figure 39. North America Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Country (2017-2028)
Figure 40. North America Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Country (2017-2028)
Figure 41. United States Benign Prostatic Hyperplasia (BPH) Drugs Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 42. Canada Benign Prostatic Hyperplasia (BPH) Drugs Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 43. Mexico Benign Prostatic Hyperplasia (BPH) Drugs Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 44. Europe Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Type (2017-2028)
Figure 45. Europe Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Application (2017-2028)
Figure 46. Europe Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Country (2017-2028)
Figure 47. Europe Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Country (2017-2028)
Figure 48. Germany Benign Prostatic Hyperplasia (BPH) Drugs Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 49. France Benign Prostatic Hyperplasia (BPH) Drugs Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 50. United Kingdom Benign Prostatic Hyperplasia (BPH) Drugs Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 51. Russia Benign Prostatic Hyperplasia (BPH) Drugs Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 52. Italy Benign Prostatic Hyperplasia (BPH) Drugs Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 53. Asia-Pacific Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Region (2017-2028)
Figure 54. Asia-Pacific Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Application (2017-2028)
Figure 55. Asia-Pacific Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Region (2017-2028)
Figure 56. Asia-Pacific Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Region (2017-2028)
Figure 57. China Benign Prostatic Hyperplasia (BPH) Drugs Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 58. Japan Benign Prostatic Hyperplasia (BPH) Drugs Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 59. Korea Benign Prostatic Hyperplasia (BPH) Drugs Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 60. India Benign Prostatic Hyperplasia (BPH) Drugs Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 61. Southeast Asia Benign Prostatic Hyperplasia (BPH) Drugs Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 62. Australia Benign Prostatic Hyperplasia (BPH) Drugs Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 63. South America Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Type (2017-2028)
Figure 64. South America Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Application (2017-2028)
Figure 65. South America Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Country (2017-2028)
Figure 66. South America Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Country (2017-2028)
Figure 67. Brazil Benign Prostatic Hyperplasia (BPH) Drugs Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 68. Argentina Benign Prostatic Hyperplasia (BPH) Drugs Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 69. Middle East & Africa Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Type (2017-2028)
Figure 70. Middle East & Africa Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Application (2017-2028)
Figure 71. Middle East & Africa Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Region (2017-2028)
Figure 72. Middle East & Africa Benign Prostatic Hyperplasia (BPH) Drugs Revenue Market Share by Region (2017-2028)
Figure 73. Turkey Benign Prostatic Hyperplasia (BPH) Drugs Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 74. Egypt Benign Prostatic Hyperplasia (BPH) Drugs Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 75. Saudi Arabia Benign Prostatic Hyperplasia (BPH) Drugs Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 76. South Africa Benign Prostatic Hyperplasia (BPH) Drugs Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 77. Manufacturing Cost Structure Analysis of Benign Prostatic Hyperplasia (BPH) Drugs in 2021
Figure 78. Manufacturing Process Analysis of Benign Prostatic Hyperplasia (BPH) Drugs
Figure 79. Benign Prostatic Hyperplasia (BPH) Drugs Industrial Chain
Figure 80. Sales Channel: Direct Channel vs Indirect Channel
Figure 81. Methodology
Figure 82. Research Process and Data Source
Please feel free to write an email to us or to use our electronic ticketing system.
